Sandoz Articles
NEW TRIAL RESULTS REPORTED AT ECCO
20 September 1993
MORE FOREIGN R&D ACTIVITY IN JAPAN
13 September 1993
EUROPEAN STOCK COMMENT
23 August 1993
US ZOFRAN APPROVAL LIFTS GLAXO SHARES
23 August 1993
SUSTAINABLE EARNINGS GROWTH FOR SANDOZ
16 August 1993
SANDOZ ACQUIRES DUTCH GROUP
9 August 1993
EUROPEAN STOCK COMMENT
2 August 1993
TANABE AND SANDOZ IN DRUG ALLIANCE
2 August 1993
SANDOZ DEAL WITH NIPPON ZOKI
2 August 1993
CANADIAN DRUG FIRMS BACK TORIES
2 August 1993
SANDOZ POSTS STRONG NET INCOME
26 July 1993
SCRIPPS IMPOSES LIMITS ON SANDOZ DEAL
19 July 1993
GIST-BROCADES BUYS SANDOZ PLANT
19 July 1993
HOECHST/SCHERING AG AGROCHEM MERGER
19 July 1993
UK INDUSTRY CODE OF PRACTICE REVIEW
19 July 1993
SANDOZ SETTLES CHARGES
12 July 1993
SANDOZ' ONCE-DAILY TROPISETRON
12 July 1993
GERMAN DRUG SALES DOWNTURN IMPROVING
12 July 1993
IMMUNOTHERAPEUTICS IN AIDS THERAPY
5 July 1993
R&D INVESTMENTS BY US GENERICS MAKERS
28 June 1993
SANDOZ/SCRIPPS DEAL TO BE FOUGHT BY US GOVT
28 June 1993
COMPETITIVE DYNAMICS IN PHARMA INDUSTRY
28 June 1993
SANDOZ APPOINTMENT
21 June 1993
ITALIAN DRUG INDUSTRY CONTRACTING
21 June 1993
SANDOZ' IL-3 SHOWS PROMISE IN CANCER
14 June 1993
JAPAN SEEING HEAVY PHARMA R&D INVESTMENT
7 June 1993
MALLINCKRODT'S OCTREOSCAN
7 June 1993
TOKYO STOCK COMMENT
7 June 1993
FIRST LAUNCH OF FUJISAWA'S PROGRAF
7 June 1993
RISPERDAL LAUNCHED IN UK
31 May 1993
GULF STATES PHARMA TENDER FORECASTS
31 May 1993
SANDOZ IL-3/GM-CSF TRIAL
24 May 1993
OTC GASTROINTESTINALS IN THE USA
24 May 1993
SANDOZ APPOINTMENTS
17 May 1993
RECOMMENDATION FOR RISPERDAL APPROVAL
17 May 1993
CIBA EXPECTS INCREASES IN 1993
17 May 1993
US DRUGMAKERS GOING IN FOR MORE LOBBYING
17 May 1993
EUROPE STOCK COMMENT
10 May 1993
TOKYO STOCK COMMENT
3 May 1993
1993 "ANOTHER GOOD YEAR" SAYS SANDOZ
3 May 1993
HHS RECOMMENDATIONS FOR ANTIDEPRESSANTS
3 May 1993
PORTUGAL'S OTC DRUG MARKET GROWING FAST
3 May 1993
SANDOZ WINS JAPANESE SUIT
26 April 1993
TOKYO STOCK COMMENT
26 April 1993
BREAST CANCER US RESEARCH UPDATE
26 April 1993
FURTHER CLUES TO CLOZARIL ACTION
26 April 1993
NEUROPHARMACEUTICAL MARKET IN USA
19 April 1993
PROTEIN DESIGN LABS ACQUIRE FIVE ANTIBODIES
19 April 1993
EUROPE STOCK COMMENT
19 April 1993
LONG-TERM CALCITONIN MAINTAINS BONE MASS
19 April 1993
BROAD SPECTRUM WAY FORWARD IN ANTIFUNGALS
12 April 1993
OTC TAVIST SHOWS RAPID GROWTH
12 April 1993
BOARD CHANGES AT SANDOZ
5 April 1993
SUPPORT FOR US DRUG FIRMS FROM NEW JERSEY
5 April 1993
1992 NET PROFITS SURGE 34% AT SANDOZ
5 April 1993
SWEDEN'S PHARMA MARKET IN 1992
5 April 1993
WAYWARD ADVERTISING OF PRODUCTS IN FRANCE
5 April 1993
WORLD ENDOCRINE MARKET AND FORECASTS
29 March 1993
SANDOZ/SCRIPPS DEAL "MONOPOLISTIC"
22 March 1993
PROGRAF HEADS NEW JAPANESE APPROVALS
22 March 1993
IS GOVT GETTING ITS RESEARCH REWARDS?
8 March 1993
CICLOSPORIN AS A MICROEMULSION
8 March 1993
ZENECA LICENSES ANTICANCER Ab THERAPY
8 March 1993
SANDOZ ESPANA RESULTS
1 March 1993
IMCLONE HEADING FOR COMMERCIALIZATION
1 March 1993
SIGNIFICANT MOVES BY PHARMA COS IN FT 500
1 March 1993
SANDOZ DEAL WITH SCRIPPS QUESTIONED
22 February 1993
NAVOBAN LAUNCH
22 February 1993
MAXIMIZING R&D AND CUTTING TIME TO MARKET
22 February 1993
WORLD CNS MARKET IS LARGE AND FRAGMENTED
22 February 1993
JAPANESE MEETING YIELDS NEW COMPOUNDS
8 February 1993
EUROPE STOCK COMMENT
8 February 1993
WORLD ANTICANCER/ IMMUNOLOGY MARKET
8 February 1993
SANDOZ 1992 SALESRISE 8%
8 February 1993
SANDOZ 1992 SALES SEE 8% INCREASE
1 February 1993
NEW CHEMICAL ENTITIES LAUNCHED IN 1992
1 February 1993
FDA APPROVES 26 NEWDRUGS IN 1992
25 January 1993
SANDOZ GRANT
25 January 1993
ALZA AND SANDOZ FILE NDA
25 January 1993
SWISS PHARMA TRADE DATA FOR 1991
25 January 1993
SANDOZ' LAMISIL APPROVED IN USA
18 January 1993
SANDOZ BUYS OUT REPLIGEN
4 January 1993
GLOBAL DRUG MARKET: 30 YEARS OF GROWTH
4 January 1993
SANDOZ, MAGAININ ANTICANCER DEAL
4 January 1993
PFIZER AND ABBOTT INDIAN PRICE MOVE
4 January 1993
CANADIAN C-91 GOES TO THE SENATE
21 December 1992
SANDOZ/SCRIPPS INST "LANDMARK" DEAL
14 December 1992
NEW ATHEROSCLEROSIS GUIDELINES FOR EUROPE
14 December 1992
ZENECA'S PROMISING R&D PIPELINE PRESENTED
14 December 1992
SANDIMMUNE GAINS NEW INDICATION IN USA
7 December 1992
EUROPE STOCK COMMENT
7 December 1992
EURO HEALTH CARE STOCK PERFORMANCE
7 December 1992
NEW APPROACHES IN TREATING PARKINSONISM
7 December 1992
COUNTING THE COST OF SCHIZOPHRENIA
7 December 1992
LEUCOMAX LAUNCH IN UK
9 November 1992
EURO GROUP FOR REGULATORY AFFAIRS
2 November 1992
NDA FOR MALLINCKRODT
2 November 1992
STOCK MARKET COMMENTARY: EUROPE
12 October 1992
ANTI-CD3 POTENTIAL DIABETES TREATMENT
12 October 1992
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
